Hematology Frontier

The recently published “Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations” in the prestigious journal Leukemia marks a historic milestone as the first international expert consensus focused on chronic-phase chronic myeloid leukemia (CML) in children and adolescents.

From April 11 to 12, 2025, the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care(CPAM) held its annual academic meeting in Qingdao, Shandong Province, alongside the “Hua Tuo Project” MDT Forum. During the event, Academician Xiaojun Huang—Conference Chair, Director of the Hematology Branch of the CPAM , and professor at Peking University People’s Hospital—delivered a landmark keynote titled "50 Years of Hematopoietic Stem Cell Transplantation." His talk provided a comprehensive review across four dimensions: historical development, China’s contributions, advances in immunotherapy, and future perspectives. He highlighted milestone achievements and global impacts—especially the original “Beijing Protocol”—and underscored how Chinese innovations are reshaping the international transplant landscape, offering valuable insights for hematologists worldwide.

The 2024 Nobel Prize in Physiology or Medicine was awarded to Victor Ambros and Gary Ruvkun in recognition of their seminal discovery of microRNAs (miRNAs) and their regulatory role in…

Leukemia represents a genetically heterogeneous group of hematologic malignancies. While most genomic studies have historically centered on somatic nuclear mutations, a growing body of evidence underscores the critical contribution of…

In China, where matched sibling or unrelated donors are often unavailable, haploidentical donor hematopoietic stem cell transplantation (HID HSCT) plays a crucial role in treating acute myeloid leukemia (AML). However,…

Hematological malignancies—including leukemia, lymphoma, myelodysplastic syndromes (MDS), and multiple myeloma—remain difficult to manage due to frequent relapse and post-transplant complications such as graft-versus-host disease. Among the emerging immunotherapeutic strategies, γδ…

Despite over 100 million units of blood being donated annually, supply remains insufficient, particularly for patients with chronic conditions or in crisis settings. Alloimmunization and blood group incompatibilities further constrain transfusion efficacy. In response, researchers are exploring the use of induced pluripotent stem cells (iPSCs) to generate red blood cells (RBCs) in vitro as a reliable and potentially limitless source of transfusable cells. The journal Blood Science (2025) presents a comprehensive review of the current progress, challenges, and future directions of iPSC-derived erythropoiesis.

Hemophilia A is a chronic bleeding disorder resulting from a deficiency in coagulation factor VIII (F8). Current treatment strategies rely on frequent F8 replacement therapy, which is limited by its short half-life, high cost, and the risk of inhibitor development. Gene therapy using adeno-associated virus serotype 8 (AAV8) has emerged as a promising modality, offering liver-targeted, long-term transgene expression. This article recently published in Blood Science investigates whether targeted deletions adjacent to the furin cleavage site of F8 can enhance the therapeutic efficacy and safety of AAV8-delivered BDDF8 constructs in a murine model of hemophilia A.

At the 2024 ASH Annual Meeting, Dr. Syed Osman Ahmed contributed to a study investigating the incidence of sinusoidal obstruction syndrome (SOS) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia…

From March 30 to April 2, the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025) was held in Florence, Italy—the cradle of the Renaissance.…